Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-α 2b treatment

@inproceedings{Ascierto2010RegulatoryTC,
  title={Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-α 2b treatment},
  author={Paolo Antonio Ascierto and Maria Napolitano and Egidio Celentano and Ester Simeone and Giusy Gentilcore and Antonio Daponte and Mariaelena Capone and Corrado Carac{\`o} and Rosa Calemma and Gerardo Beneduce and Margherita Cerrone and Vincenzo de Rosa and Giuseppe Palmieri and Giuseppe Castello and John Munn Kirkwood and Francesco M. Marincola and Nicola Mozzillo},
  booktitle={Journal of Translational Medicine},
  year={2010}
}
High-dose interferon-alpha 2b (IFN-α 2b) is the only approved systemic therapy in the United States for the adjuvant treatment of melanoma. The study objective was to explore the immunomodulatory mechanism of action for IFN-α 2b by measuring serum regulatory T cell (Treg), serum transforming growth factor-β (TGF-β), interleukin (IL)-10, and autoantibody levels in patients with melanoma treated with the induction phase of the high-dose IFN-α 2b regimen. Patients with melanoma received IFN-α 2b… CONTINUE READING